Arius Starts Pre-Clinical Study for Cancer Drug
Posted on: Tuesday, 24 July 2007, 06:21 CDT
Arius Research has initiated the first study in the formal preclinical toxicology program for its lead anti-CD44 drug candidate, which is under development for the treatment of breast, prostate and liver cancers.
Arius said that it expects to file an IND application and begin human clinical trials in 2008. The biotechnology company is developing the compound for the treatment of solid tumors such as breast, prostate and liver cancers. The drug targets cancer stem cells which are suspected of causing the spread of cancer even after patients appear to have responded to conventional treatments.
Dr Robert Gundel, chief scientific officer of Arius, said: "A novel antibody that targets cancer stem cells as part of its mechanism of action represents a new approach to cancer treatment with the potential of better efficacy and less toxicity for patients."
Source: Datamonitor
Related Articles
- Deaconess Hospital Installs Revolutionary Cancer Treatment System - 3-D Imaging Allows More Accurate Identification and Treatment of Cancerous Tumors
- Deaconess Hospital in OKC Installs New Cancer Treatment System
- Pregnancy Hope for Women After Cancer Treatment
- Breast Cancer Treatment in the U.K.: June 22, 2005
- New Advances in Breast Cancer Treatment Fueled By BCRF Support
- Elekta Selected By Canadian World Leader in Cancer Treatment
- Genentech Cancer Treatment Shows Promise
- Updates on Breast Cancer Treatment in the U.K.
- Research and Markets: New Report Examines Hot Topics and Key Issues for Prostrate Cancer Treatment
- New Breast Cancer Treatment May Help Thousands of Women Get Back on Track Faster
 |
 |
User Comments (0)
RSS Feeds